|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, November 12, 2016 ) PharmaPoint: Parkinsons Disease - Japan Drug Forecast and Market Analysis to 2022
Summary
Parkinsons disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinsons disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=197510
The aging population in Japan is growing at an accelerated rate compared with other countries forecast in this report, accounting for the significant hike in sales during the 10-year forecast, along with low rates of generic substitution. Several products will be launched between 2012 and 2016, with some losing patent life during the same forecast period.
Scope
- Overview of Parkinsons Disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Japan from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the Japan Parkinsons Disease market.
Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html
Table of Contents
1 Table of Contents 5
1.1 List of Tables 9
1.2 List of Figures 12
2 Introduction 13
2.1 Catalyst 13
2.2 Related Reports 13
3 Disease Overview 16
3.1 Etiology and Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 19
3.1.3 Prognosis 21
3.1.4 Quality of Life 22
3.2 Symptoms 22
4 Disease Management 24
4.1 Overview 24
4.1.1 Diagnosis - The UK Brain Bank Criteria 24
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 25
4.2 Treatment Synopsis 26
4.2.1 Dopaminergic Therapy Classes 27
4.2.2 Treatment of Parkinsons disease by Stage 29
4.2.3 Other Treatment Options 32
4.3 Parkinsons Disease Assessment Scales 32
4.3.1 Unified Parkinsons Disease Rating Scale (UPDRS) 33
4.3.2 Hoehn and Yahr Clinical Staging 35
4.3.3 Other Clinical Assessments 36
4.4 Diagnosis and Treatment of Parkinsons Disease by Country 36
4.4.1 Japan 36
Contact Us:
Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Researchmoz Global Pvt.Ltd
Researchmoz
+1-518-621-2074
sales@researchmoz.us
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
